Celgene and Pfizer returned for small molecule drug developer Arrakis Therapeutics' latest round, which included GV and Wuxi AppTec Fund.

Osage University has returned for a $75m series B round raised by Arrakis Therapeutics, which has licensed technology from University of Pennsylvania.

The healthcare integration platform has increased its total funding to approximately $47m with the Intermountain Healthcare-backed round.

Each week the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Scott Morley has been appointed as director of the Coulter@Pitt medtech accelerator, in addition to his duties as entrepreneur-in-residence at the university's Innovation Institute.

Gyroscope Therapeutics, spun out of Cambridge and Syncona, has merged with Orbit Biomedical to form a fully-integrated retinal gene therapy developer.

Ascension Health and UNC Rex Healthcare have both contributed to a $35.5m round that will support the development of Bardy's lightweight cardiac monitor.

IDF Innov-allied brain implant developer Neurallys plans to market sensors that measure intracranial pressure to combat the severe neurological complication hydrocephalus.

Eli Lilly and GSK-backed precision oncology drug developer Turning Point Therapeutics floated at the top of its range while expanding the number of shares it issued.

Alexandria Real Estate Equities-backed molecular therapy developer Applied Therapeutics is aiming for $86.3m in its initial public offering.